4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $117,720.00 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. This represents a 53.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock opened at $11.60 on Friday. The stock has a fifty day moving average price of $9.58 and a two-hundred day moving average price of $9.16. 4D Molecular Therapeutics, Inc. has a 52-week low of $3.68 and a 52-week high of $12.34. The firm has a market capitalization of $606.45 million, a P/E ratio of -4.51 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. On average, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Chardan Capital reissued a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Jefferies Financial Group reiterated a “buy” rating and issued a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Finally, Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $29.88.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE increased its stake in shares of 4D Molecular Therapeutics by 17.0% in the 1st quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock valued at $9,070,000 after buying an additional 141,582 shares during the period. Janus Henderson Group PLC lifted its stake in shares of 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after acquiring an additional 611,276 shares during the period. Exome Asset Management LLC bought a new position in 4D Molecular Therapeutics in the first quarter valued at about $1,216,000. Renaissance Technologies LLC boosted its holdings in 4D Molecular Therapeutics by 12.7% in the first quarter. Renaissance Technologies LLC now owns 578,265 shares of the company’s stock valued at $5,384,000 after acquiring an additional 65,365 shares during the last quarter. Finally, Sei Investments Co. increased its position in 4D Molecular Therapeutics by 8.9% in the first quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock worth $120,000 after purchasing an additional 1,050 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.